linjc16/ctgov huggingface dataset:
The Association Between Shock Index and Severity of Postpartum Blood Loss

Study Overview
=================
Brief Summary
-----------------
The present study aims to determine the relationship between postpartum changes in the shock index and the severity of blood loss and other PPH results. Blood loss, heart rate and blood pressure will be systematically measured in the postpartum period in all participating women to explore new clinical indicators to identify those requiring clinical intervention for excessive bleeding.

Official Title
-----------------
The Association Between Shock Index and Severity of Postpartum Blood Loss: An Observational Study

Conditions
-----------------
Postpartum Hemorrhage

Intervention / Treatment
-----------------
* Other: Exposure to vaginal delivery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Receive care for vaginal delivery Exclusion Criteria: Scheduled or transferred for cesarean section Cannot give informed consent Are not willing and/or cannot answer the questionnaire on their background
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women in labor<br>All participants who have a vaginal delivery | Other: Exposure to vaginal delivery<br>* Women who have vaginal births are observed for a minimum of 1 hour postpartum<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between blood loss and shock index | Correlate shock index, heart rate, and blood pressure measurements with blood loss levels at 15, 30, 45 & 60 minutes | Within 1 hour postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of women with blood loss ≥ 500 ml and ≥ 1000 ml | Proportions with ≥ 500 ml and ≥ 1000 ml blood loss at 30 and 60 minutes postpartum, at PPH diagnosis (if applicable), and when active bleeding stops | Up to two hours postpartum | 
| Median blood loss in the postpartum and interquartile range | Blood loss at 30 and 60 minutes postpartum, at PPH diagnosis (if applicable), and when active bleeding stops | Up to two hours postpartum | 
| Percentage of women who received treatment to control bleeding |  | Up to two hours postpartum | 
| Average change in Hb measured before and after delivery | Among women receiving treatment to control postpartum hemorrhage | Pre-delivery and at least 24 hours postpartum | 
| Percentage of women with complications | Among women receiving treatment to control postpartum hemorrhage | Through study completion, an average of 24-48 hours postpartum |
Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to describe the pulmonary hemodynamic evolution at rest and during a short constant load exercise in 4 conditions : normoxia hypoxia hypercapnia association hypoxia and hypercapnia

Official Title
-----------------
Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic

Conditions
-----------------
Pulmonary Vascular Sensibility in Hypoxia, Hypercapnia, Hypoxia and Hypercapnia

Intervention / Treatment
-----------------
* Device: Hypercapnia inhalation (Altitrainer NP 190)
* Device: Hypoxia and hypercapnia (Altitrainer NP 190)
* Device: Hypoxia inhalation (Altitrainer NP 190)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: healthy male exercise capacity between 100 and 130 % of theorical values Exclusion criteria: smoker headache impossibility to perform an exercise test no tricuspid regurgitation on the echocardiography

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HYPOXIA<br> | Device: Hypoxia inhalation (Altitrainer NP 190)<br>* Hypoxia inhalation using an Altitrainer NP 190<br>|
| HYPERCAPNIA<br> | Device: Hypercapnia inhalation (Altitrainer NP 190)<br>* Hypercapnia inhalation using an Altitrainer NP 190<br>|
| HYPOXIA + HYPERCAPNIA<br> | Device: Hypoxia and hypercapnia (Altitrainer NP 190)<br>* Hypoxia and hypercapnia inhalation using an Altitrainer NP 190<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic Artery Pulmonary Pressure(sPAP) (echocardiography, Cardiac output (impedancemetry), Cardiorespiratory parameters | At rest and during exercise for each condition | at the end of the 30th minutes constant load exercise | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspnea and muscle leg discomfort using a Borg Scale | In each conditions at rest and during exercise | at the end of the 30th minutes constant load exercise |
The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study

Study Overview
=================
Brief Summary
-----------------
We will performe a prospective randomized study to evaluate the effects of the addition of alfuzocine xl 10 mg once a day for the conservative treatment of selected ureteral stones. A total of 60 patients with distal ureteral calculi will randomly divide into two treatment groups: group A (n=30) who will receive only analgetic therapy(Dipyrone)and diclofenac i.m. 75mg and group B (n=30) who will receive the same therapy plus alfuzocin xl (10 mg/daily) for a maximum of 2 weeks.No significant differences will be between the groups for age, gender distribution and mean stone size measured in the single largest dimension at presentation.Randomization will be done only with the patients permission after they had read a summary describing the goals of conservative management and a description of the drugs they would be taking. Potential side effects and complications of the drugs were discussed. The expulsion rate will the primary end-point of this study.

Conditions
-----------------
Distal Ureterolithiasis

Intervention / Treatment
-----------------
* Drug: Alfuzocine XL 10 mg once a day


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stone in the distal ureter until 1 cm of diameter Exclusion Criteria: Evidence of urinary tract infection or sepsis Moderate or severe hydronephrosis Acute renal failure Ureteral stricture Stone with >1cm of diameter Previuos use of alpha blocker Pregnancy Previuos ureteral endoscopic or open surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Alfuzocine XL 10 mg once a day|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients

Study Overview
=================
Brief Summary
-----------------
Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients

Detailed Description
-----------------
This is a prospective study to evaluate the safety of donor nephrectomy in HIV+ individuals who donate kidneys to HIV+ candidates in need of transplant . The study will assess potential complications of HIV + living donors - including adverse events related to nephrectomy, development of chronic kidney disease, hypertension, and HIV-related complications.

Official Title
-----------------
Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients

Conditions
-----------------
HIV Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to understand and provide consent Age 21 years or older Meets standard clinical criteria for living donation per Johns Hopkins University (JHU) Comprehensive Transplant Center Policy Documented HIV infection (by any licensed Enzyme-linked Immunosorbent Assay (ELISA) and confirmation by Western Blot, positive HIV Ab Immunofluorescent Assay (IFA), or documented history of detectable HIV-1 RNA) CD4+ T-cell count ≥ 500/µL for 6 months prior to donation HIV-1 RNA below 50 copies RNA/mL (viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements >200 copies/mL) Exclusion Criteria: Two high risk alleles of APOL1 (G1 or G2 variants) Hypertension Diabetes Chronic active hepatitis C (detectable HCV RNA in plasma) Evidence of invasive opportunistic complications from HIV infection Mentally incompetent and/or inability to provide informed consent Other medical conditions, as determined by the provider, that would preclude donation

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | incidence of adverse events related to nephrectomy | at 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| chronic kidney disease | time to significant proteinuria or glomerular filtration rate below 60 ml/min | through to study completion, up to 4 years | 
| hypertension | time to hypertension defined as systolic blood pressure > 140 mm Hg confirmed | through to study completion, up to 4 years | 
| change in antiretroviral therapy | proportion of participants requiring change in antiretroviral therapy | through to study completion, up to 4 years | 
| HIV virologic control | proportion of participants with HIV virologic failure or breakthrough | through to study completion, up to 4 years |
Effect of Left Atrial Ablation on Left Atrial Appendage Emptying Flow Velocity

Study Overview
=================
Brief Summary
-----------------
Consecutive patients with paroxysmal AFib scheduled to undergo pulmonary vein isolation either with radiofrequency (RF) or cryoballoon will be included. Left atrial appendage emptying flow velocity (LAA-EFV) will be measured with transesophageal echocardiography (TEE) immediately before and following left atrial ablation (1 month post). The change in LAA-EFV will be compared between the two groups (RF versus Cryo).

Official Title
-----------------
Differential Effect of Radiofrequency and Cryoballoon Ablation on Left Atrial Appendage Emptying Flow Velocity

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Pulmonary vein isolation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Paroxysmal atrial fibrillation, no absolute contraindication for anticoagulation Exclusion Criteria: Previous cardiac surgery Previous left atrial ablation History of cerebrovascular event Presence of LAA thrombus Inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RF<br>Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation | Procedure: Pulmonary vein isolation<br> <br> |
| Cryoballoon<br>Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation | Procedure: Pulmonary vein isolation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LAA-EFV | Left atrial appendage emptying flow velocity | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LAA-EFV | Left atrial appendage emptying flow velocity | 3 months |
Quality of Handover to a Post Anaesthesia Care Unit in a Children's Hospital

Study Overview
=================
Brief Summary
-----------------
Postoperative handovers to the post anaesthesia care unit (PACU) in adult anaesthesia are described as incomplete and unstructured, although their relevance for the patient safety is well known. It must be assumed that for children, this handover is at least comparable important. With a self-developed checklist information transfer during postoperative handovers will be documented and subsequently compared with patient information in anaesthesia records.

Conditions
-----------------
Information Transfer During Postoperative Handovers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients transferred to the PACU after surgery Exclusion Criteria: Age > 18 years

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantity of Information Loss during Postoperative Handovers in the PACU |  | Three month |
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

Study Overview
=================
Brief Summary
-----------------
This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.

Conditions
-----------------
Hyperhidrosis

Intervention / Treatment
-----------------
* Biological: Botulinum toxin type A
* Biological: Botulinum toxin type A
* Biological: Placebo comparator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary axillary hyperhidrosis Female or male, 18 years of age or older in good general health Excessive sweating interferes with daily life activities and scores 3 or 4 on the HDSS at Screening and Baseline Axillary sweat production of at least 50 mg/5 min measured gravimetrically Exclusion Criteria: Any neurological condition, that may place the subject at increased risk with exposure to botulinum toxin type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and Myasthenia gravis Muscle weakness or paralysis, particularly in the upper extremities Active skin disease or irritation or disrupted barrier at the treatment area Undergone any procedures which may affect the axillary areas Treatment with botulinum toxin type A in the axilla in the last 9 months or anywhere in the body in the last 6 months Any prior axillary use of an anti-hyperhidrosis medical device If menopausal had symptoms of menopause such as sweating or flushing within the last year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dose A<br>Botulinum toxin type A | Biological: Botulinum toxin type A<br>* Botulinum toxin type A, Dose A, Topical<br>|
| Experimental: Dose B<br>Botulinum toxin type A | Biological: Botulinum toxin type A<br>* Botulinum toxin type A, Dose B, Topical<br>|
| Placebo Comparator: Dose C<br>Placebo comparator | Biological: Placebo comparator<br>* Placebo, Dose C, Topical<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hyperhidrosis Disease Severity Scale (HDSS) | Improvement at follow-up in the experimental groups compared to the placebo group | Week 4 | 
| Gravimetry | The amount of sweat measured gravimetrically | Week 4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dermatology Life Quality Index (DLQI) |  | Week 4 |
Measured Hypocretin Levels and Recovery After Hip Surgery

Study Overview
=================
Brief Summary
-----------------
A specific group of neurons in the brain produces hypocretin, a peptide which has been established as an important regulator of sleep and wakefulness. Activation of these neurons (increased hypocretin) stabilizes wakefulness; impairing or blocking these neurons (decreased hypocretin) promotes sleep. Evidence suggests that these neurons may be involved in the hypnotic properties of several anesthetics, and play a role in the induction and emergence from anesthesia. In humans there is a considerable inter-individual variability in hypocretin levels. This study aims to investigate how hypocretin levels affect the anesthetic care and recovery of patients undergoing elective hip surgery.

Official Title
-----------------
Preoperative Cerebrospinal Fluid (CSF) Levels of Hypocretin and Recovery After Hip Surgery With Combined Spinal and General Anesthesia

Conditions
-----------------
Osteoarthritis, Hip

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- Adult (18 years of age or older) Male or female Scheduled for elective total hip arthroplasty at the Stanford Orthopedic Clinic. Comprehend spoken and written English Exclusion Criteria:- ASA physical status > III (patients with severe systemic disease) Diagnosed psychiatric disease (except mild depression) Any diagnoses CNS disease or dementia History of stroke History of untreated thyroid disease Difficulty in airway management (ventilation and/or intubation) Body Mass Index (BMI) > 35 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anesthetic Recovery Times | recovery from anesthesia will be measured by short-term outcomes like time to tracheal extubation and response to verbal commands, as well as by psycho-vigilance testing up to 72 hours postoperatively | 0-72 hours after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity to sevoflurane during inhalation induction to anesthesia, determined by bispectral index of the EEG | pharmacodynamic analysis of bispectral index of the EEG response to sevoflurane | during anesthetic induction | 
| pain and sleepiness | assessment of pain and sleepiness using the numerical rating scale (0-10) during the 72 hours postoperatively | from 0-72 hours after surgery |
A Comparison of Radiographic and Visual Analysis Methods for Determining Pelvic Misalignments.

Study Overview
=================
Brief Summary
-----------------
This study looks to compare pelvic misalignments visualized during patient inspection to actual pelvic misalignments derived from x-ray mensuration.

Detailed Description
-----------------
This study looks to compare pelvic misalignments of 30 subjects visualized before x-ray set up to the actual misalignments derived from x-ray mensuration. 30 outpatients at the Sherman College of Chiropractic Health Center were randomly chosen to participate, and were having x-rays taken as part of their normal course of care in order prevent unnecessary radiation exposure. Patients were told to march in place as they were positioned to the x-ray bucky. Once the patient was set to the bucky, the bucky was moved out of the way and the patient was visualized by a health center intern. The intern evaluated gluteal widths, gluteal fold heights, and foot flare. The bucky was then replaced without patient movement and x-rays were then taken. Two doctors with experience in Gonstead line analysis for the pelvis who were blinded to the x-ray findings, measured pelvic misalignments and the results were compared to the visual analysis.

Official Title
-----------------
A Comparison of Radiographic and Visual Analysis Methods for Determining Pelvic Misalignments.

Conditions
-----------------
Gonstead, Chiropractic, Pelvic Analysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Receiving x-rays as part of their normal course of care at the Sherman College of Chiropractic Health Center - There were no exclusion criteria -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A Comparison of Radiographic and Visual Analysis Methods for Determining Pelvic Misalignments. | visual analysis of the pelvis should correlate to radiographic mensuration | 7 months |